article thumbnail

Generic drugmaker Hikma pledges $1bn in US investment

pharmaphorum

With tariffs looming, Indian drugmaker Hikma has said it will spend $1bn to expand its manufacturing and R&D operations in the US by 2030.

article thumbnail

AstraZeneca announces $50bn US investment plans by 2030

Pharmaceutical Technology

AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D). It will also support our ambition to reach $80bn in revenue by 2030.” Credit: grandbrothers/Shutterstock.com.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Five for Friday July 18: Celebrating Success in Advancing Medication Use Quality

PQA

PQA is developing its next strategic plan, Blueprint PQA 2030, which will guide the organization’s work from 2026 through 2030. As with PQA’s 2021 summit, this year’s summit will leverage PQA members’ expertise to inform the strategies and tactics that will be key to success through 2030. Welcome to Five For Friday!

article thumbnail

STAT+: The end of compounded GLP-1 copies leaves many patients in a ‘lose-lose’ position

STAT

  The companies also see compounders as a threat to their obesity drug sales, which are estimated to balloon to $100 billion a year by 2030. (The FDA has received more than 700 adverse event reports tied to compounded GLP-1s, but it’s not clear if the events were caused by the drugs.) 

article thumbnail

Next drug patent cliff to challenge Big Pharma strategy

European Pharmaceutical Review

Only a few big pharma companies are positioned to grow revenue sustainably through 2030, stated GlobalData. As such, the US market is expected to lose over $230 billion over the next five years. Which blockbuster drugs could be impacted in the next pharmaceutical patent cliff?

article thumbnail

3 major patent losses this year — and a key strategy to fill the gaps

PharmaVoice

EY data underscores the urgency of this marketing transformation to mitigate potential revenue losses estimated at $230 billion by 2030. “A lot of companies are trying now to figure out how to use digital assets better, but its a very slow adoption in the marketplace,” Schur said.

FDA
article thumbnail

Flu Fighters: Pharmacists Partnering to Protect Communities

Pharmacy Times

of US adults received a vaccine, far short of the Healthy People 2030 target of 70%. Healthy People 2030. Meet Communities Where They Are Although influenza vaccines are widely available, vaccination rates remain below national goals. During the 2023-2024 influenza season, only 44.9% Accessed June 10, 2025. September 20, 2024.